Arthneeti
B

Biocon

Q1 FY27Pharmaceuticals & Biotechnology

Biocon Q1 FY27 earnings call: Revenue & Margins

Q1 FY27 earnings call: what management guided on revenue, margins and order book.

Price₹415
Market cap₹67.7K Cr
P/E93.1
Updated25 Aug 2026
Read5 min read

What the Q1 FY27 call signalled

0 of 3 strong

RevenueModerate growth
MarginMargins steady
CapexNo capex planned

The short version

Biosimilars business expected to see meaningful acceleration in second half of FY27 with new product launches driving growth (Page 6, 9, 10). Biosimilars business expected to show meaningful acceleration in growth, especially in the second half of FY27, driven by recent launches and expanded manufacturing capacity.

From Biocon's Q1 FY27 earnings-call transcript · updated 25 Aug 2026.

Revenue & Sales Performance

Moderate growth
  • Biosimilars business expected to see meaningful acceleration in second half of FY27 with new product launches driving growth (Page 6, 9, 10).
  • Generics business showing healthy revenue growth (21% YoY) with new launches like liraglutide contributing; further scale-up expected (Page 7, 10).
  • Continued new product launches planned annually in biosimilars through the end of the decade to sustain growth (Page 17).
  • Insulin franchise expansion supported by manufacturing capacity increase with EMA approval, expected to drive global demand (Page 6).
  • Aflibercept launched in US ophthalmology market with strong growth opportunities anticipated (Page 9, 15).
  • Focus on calibrated profitable growth rather than just market share to ensure sustainable revenue and margin expansion (Page 9, 18).

2 more points from Biocon's call on revenue

Every concall, every company

Profitability & Margins

See what Biocon said on profitability & margins — free account, 30 seconds.

Capital Expenditure Plans

No capex planned
  • Biocon currently holds a small stake in Bicara but is not contemplating monetizing it immediately; monetization will be considered at the right time given Bicara's strong performance (Page 21).
  • Regarding manufacturing in the USA, Biocon does not plan to increase capital expenditure to establish new facilities or capacities; instead, they focus on partnerships and utilizing existing manufacturing facilities (Page 20).
  • The Biocon Group is looking at having a local manufacturing footprint where needed, primarily through partnerships rather than building new plants (Page 20).

2 more points from Biocon's call on capex

Every concall, every company

Top-ranked in Pharmaceuticals & Biotechnology

Ranked on what management guided this quarter

Guidance-ranked
1Accretion Pharmaceuticals Ltd
Rev 1Mar 2
2OneSource Specialty Pharma Ltd
Rev 1Mar 3
3
Rev 2Mar 1
4
Rev 2Mar 2
5
Rev 2Mar 2
Sign up free to see 3 moreTakes 30 seconds · no cardSign up

Rank buckets describe management commentary on revenue and margin. Not investment advice, and not a forecast of returns.

Fundraising & Capital Structure

See what Biocon said on fundraising & capital structure — free account, 30 seconds.

Order Book & Pipeline

The transcript does not provide explicit details on the current or expected order book or pending orders for Biocon Limited. However, the following relevant points can be inferred: - Biosimilars business is the core growth engine with strong traction and expanded manufacturing capability. - Momentum is expected to build progressively through FY27 with meaningful acceleration in the second half. - New product launches, including biosimilars and generics, are scaling up to contribute to revenue growth. - The company is prepared for increased demand, supported by manufacturing milestones such as EMA approval of new insulin production lines. - Focus remains on profitable growth, balancing new launches with operational efficiencies.

2 more points from Biocon's call on order book

Every concall, every company

Biocon — Quarterly revenue & net profit

Revenue Net profit Net loss
Dec 2024
Mar 2025
Jun 2025
Sep 2025
Dec 2025
Mar 2026

Reported quarterly figures (₹ Cr). Latest: revenue ₹4.5K Cr, net profit ₹199 Cr. Revenue and profit are scaled separately — hover a quarter for exact figures.

Full financials →

Continue your research

What Biocon's management said in earlier quarters

🔎 Who's planning the most growth?

Companies ranked by management's own guidance — revenue, margins, capex and order book, from every earnings call in India.

See rankings →

Arthneeti Pro · Annual

Biocon and 1,500+ more calls,
for less than your morning chai

a day

Every earnings call, ranking and concall Q&A across all four results seasons.

Secure Razorpay payment · instant access

Frequently Asked Questions

What were Biocon Q1 FY27 results?

Biosimilars business expected to see meaningful acceleration in second half of FY27 with new product launches driving growth (Page 6, 9, 10). Biosimilars business expected to show meaningful acceleration in growth, especially in the second half of FY27, driven by recent launches and expanded manufacturing capacity.

What is Biocon share price analysis?

Biocon currently shows a below-average growth signal. The stock trades at a P/E of 93.1 with a market cap of ₹67,722 Cr. Investors should review the full earnings analysis for detailed insights.

Is Biocon planning capital expenditure?

Biocon currently holds a small stake in Bicara but is not contemplating monetizing it immediately; monetization will be considered at the right time given Bicara's strong performance (Page 21).

Keep Biocon on your radar — track it to get its next earnings analysis in your feed.

This analysis is AI-generated based on publicly available earnings data and the company's earnings call transcript. This is not investment advice. Please consult a SEBI-registered advisor before making investment decisions.